These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37442994)

  • 1. PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma.
    Wu J; Shi C; Li H; Song W; Huang S; Zhang J; Li W; Li Z; Zhang M
    BMC Med; 2023 Jul; 21(1):253. PubMed ID: 37442994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
    Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
    Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.
    Gao Y; Feng X; Song W; Li H; Shi C; Jin M; Li Z; Zhang L; Zhang M
    Hematol Oncol; 2022 Oct; 40(4):678-688. PubMed ID: 35439335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
    Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
    Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma.
    Zhu L; Zhang X; Fu X; Li Z; Sun Z; Wu J; Wang X; Wang F; Li X; Niu S; Ding M; Yang Z; Yang W; Yin M; Zhang L; Zhang M
    J Cell Biochem; 2019 Aug; 120(8):12628-12637. PubMed ID: 30825244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation.
    Ma H; Shen L; Yang H; Gong H; Du X; Li J
    IUBMB Life; 2021 Jan; 73(1):108-117. PubMed ID: 33205540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells.
    He C; Wang C; Liu H; Shan B
    BMC Cancer; 2022 Jul; 22(1):724. PubMed ID: 35778693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma.
    Liu S; Li C; Xin P; Zheng Y; Peng Q; Xu Y; Luo Y; Wu Y; Zhu X
    Med Sci Monit; 2019 Nov; 25():8579-8586. PubMed ID: 31724562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
    Xu Z; Li C; Zhou Q; Deng Z; Tong Z; Tse MK; Zhu G
    Inorg Chem; 2019 Dec; 58(23):16279-16291. PubMed ID: 31738050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of latent transforming growth factor-β (TGF-β)-binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF-β/Smad and p38
    Lin R; Li X; Wu S; Qian S; Hou H; Dong M; Zhang X; Zhang M
    Exp Cell Res; 2021 Oct; 407(1):112790. PubMed ID: 34418460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma.
    Zhang P; Shi C; Song Y; Li Z; Zhang M; Jin M
    Hematol Oncol; 2022 Dec; 40(5):941-952. PubMed ID: 35797410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of sonic hedgehog signaling blocks cell migration and growth but induces apoptosis via suppression of FOXQ1 in natural killer/T-cell lymphoma.
    Liu P; Chen L
    Leuk Res; 2018 Jan; 64():1-9. PubMed ID: 29132010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
    Hiroki H; Akahane K; Inukai T; Morio T; Takagi M
    Int J Hematol; 2023 May; 117(5):748-758. PubMed ID: 36575328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
    Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
    Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy.
    Scuoppo C; Zha S
    Cancer Cell; 2019 Sep; 36(3):211-212. PubMed ID: 31526755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.